Under the agreement, GSK will retain the existing rights for these products in countries outside the US, except for Daraprim in Canada, where rights will also be divested to CorePharma.
Additionally, these brands are expected to be marketed in the US by Amedra Pharmaceuticals, a new subsidiary of CorePharma.
CorePharma CEO Christopher Worrell said that the acquisition of these products would play an important strategic role in their growth.
"The organisational strengths that we have developed at CorePharma will provide a foundation for our efforts with our new subsidiary, Amedra," Worrell said.
As per the terms of the agreement, GSK will be responsible for the supply of Albenza to CorePharma and will be also involved in the Daraprim supply chain.